SCHEMBL24324008

SCHEMBL24324008

C[C@@H]1CCCN1c1cncc(C=O)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 2/20 0.41
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
PDE10A Q9Y233 4/20 0.35
CHRM4 P08173 3/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
SYK P43405 1/20 0.33
KHK P50053 2/20 0.33
LATS1 O95835 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29600541 0.96 ALDH1A1 (0.39) SMPD3CHRM4PIM1PIM3PIM2
SCHEMBL24323682 0.96 ALDH1A1 (0.39) SMPD3CHRM4PIM1PIM3PIM2
SCHEMBL24269963 0.77 PDE10A (0.42) SMPD3ADORA2AADORA1PDE10ACHRM4
SCHEMBL24269964 0.77 PDE10A (0.42) SMPD3ADORA2AADORA1PDE10ACHRM4
SCHEMBL24324615 0.73 SMPD3 (0.41) SMPD3ADORA2AADORA1PDE10APIM1
SCHEMBL29601220 0.73 SMPD3 (0.41) SMPD3ADORA2AADORA1PDE10APIM1
SCHEMBL1326128 0.73 JAK3 (0.40) SMPD3ADORA2AADORA1PDE10ACHRM4
SCHEMBL1326312 0.73 ALDH1A1 (0.44) SMPD3CHRM4PIM1PIM3PIM2
SCHEMBL6214234 0.73 PDE10A (0.48) PDE10APIM2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL24324614 0.72 ADORA2A (0.39) SMPD3ADORA2AADORA1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150377-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2024-05-09 US disclosed
EP-4225765-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 EP disclosed
WO-2022076622-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed
WO-2022076622-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150377-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B SMPD3 246/4885ADORA2A 1767/4885ADORA1 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.